Glioblastoma Multiforme Treatment Market
PUBLISHED: 2024 ID: SMRC25981
SHARE
SHARE

Glioblastoma Multiforme Treatment Market

Glioblastoma Multiforme Treatment Market Forecasts to 2030 - Global Analysis By Type (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy and Other Types), Drug Class (Temozolomide, Lomustine, Bevacizumab, Carmustine Wafers and Other Drug Classes), Application, End User and by Geography

4.0 (89 reviews)
4.0 (89 reviews)
Published: 2024 ID: SMRC25981

This report covers the impact of COVID-19 on this global market
Loading...

Years Covered

2021-2030

Estimated Year Value (2023)

US $2.75 BN

Projected Year Value (2030)

US $5.96 BN

CAGR (2023 - 2030)

11.7%

Regions Covered

North America, Europe, Asia Pacific, South America, and Middle East & Africa

Countries Covered

US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa

Largest Market

North America

Highest Growing Market

Asia Pacific


According to Stratistics MRC, the Global Glioblastoma Multiforme Treatment Market is accounted for $2.75 billion in 2023 and is expected to reach $5.96 billion by 2030 growing at a CAGR of 11.7% during the forecast period. Chemotherapy, radiation therapy, and surgery are frequently used in the treatment of glioblastoma multiforme (GBM). The goal of surgery is to remove as much of the tumor as possible without endangering vital brain areas. Due to the infiltrative nature of GBM cells, complete removal is frequently difficult. Radiation therapy is used after surgery to target any cancer cells that may still be present and to reduce the tumor. Moreover, the next step in the treatment is chemotherapy, which frequently uses temozolomide to further target and kill cancer cells.

According to the American Cancer Society, Cancer is the second leading cause of death in the United States, exceeded only by heart disease. In 2021, about 1,898,160 new cancer cases are expected to be diagnosed and 608,570 Americans are projected to die from cancer.

Market Dynamics: 

Driver: 

Increased frequency of brain tumours

GBM is among the brain tumors that are becoming more commonplace globally. The aging of the population, exposure to the environment, genetic predispositions, and lifestyle choices are some of the factors that contribute to this trend. GBM incidence is predicted to increase in step with the world population's continued growth and aging. Furthermore, contributing to the reported rise in prevalence are developments in medical imaging and diagnostic methods that have made brain tumors easier to identify early.

Restraint:

Limited effectiveness of available therapies

The effectiveness of existing treatments for GBM is still restricted, even with improvements in treatment modalities. Chemotherapy, radiation therapy, and surgical resection can only delay the progression of the disease and reduce tumor size, offering only short-term relief. However, GBM cells frequently infiltrate the brain's surrounding tissue, making surgical removal difficult and increasing the likelihood of tumor recurrence. Additionally, the blood-brain barrier limits the effectiveness of targeted agents and chemotherapy by preventing them from reaching the brain through systemic therapies.

Opportunity:

Developments in the field of precision medicine

Optimizing treatment plans based on unique patient attributes is known as precision medicine, and it offers a bright future for enhancing GBM outcomes. Personalized treatment approaches have been made possible by the recent developments in genomic sequencing technologies and molecular profiling, which have demonstrated the heterogeneity of GBM tumors. Clinicians can select targeted therapies with a lower chance of off-target effects by identifying the precise genetic alterations and molecular signatures driving tumor growth. Furthermore, a thorough grasp of tumor biology and treatment vulnerabilities is made possible by the integration of multiomic data, such as transcriptomics, proteomics, metabolomics, and genomics.

Threat:

Tumour recurrence and therapeutic resistance

A major obstacle to the management of GBM is therapeutic resistance, which can result in tumor recurrence and the advancement of the disease. Chemotherapy, radiation therapy, and targeted agents are among the common treatment modalities to which GBM cells show both intrinsic and acquired resistance. Genetic alterations, the initiation of alternative signaling pathways, apoptosis avoidance, and the existence of cancer stem cells capable of self-renewal are examples of resistance mechanisms. Moreover, total surgical resection is difficult due to the highly infiltrative nature of GBM tumors, which leaves residual disease and the possibility of regrowth.

Covid-19 Impact: 

The market for GBM treatments has been impacted by the COVID-19 pandemic in many ways. The pandemic's early effects on healthcare systems around the world caused delays in GBM patient diagnoses, starts of treatments, and enrolment in clinical trials; however, the long-term effects have been uneven. On the one hand, the pandemic accelerated the adoption of virtual care delivery models and remote patient monitoring by highlighting the significance of telemedicine solutions and robust healthcare infrastructure. However, financial limitations, disruptions in the supply chain, and the reallocation of resources have presented difficulties for both patients and healthcare providers, potentially preventing access to prompt and effective GBM treatment.

The Surgery segment is expected to be the largest during the forecast period

When it comes to treating glioblastoma multiforme (GBM), the surgery segment usually commands the largest market share. The goal of surgery is to remove as much of the tumor as possible while maintaining neurological function, which is a critical part of managing GBM. Surgical resection is still the main treatment option for debulking the tumor and reducing symptoms, even though GBM is infiltrative in nature. Modern methods like intraoperative imaging and fluorescence-guided surgery help neurosurgeons achieve the safest resection possible. However, because GBM cells are invasive and there is a chance of brain damage, complete surgical removal is frequently challenging.

The Temozolomide segment is expected to have the highest CAGR during the forecast period

In the market for Glioblastoma Multiforme (GBM) treatments, the temozolomide segment has the highest compound annual growth rate (CAGR). One of the mainstays of GBM chemotherapy is temozolomide, an oral alkylating agent that is often taken as part of the standard treatment plan after radiation therapy and surgical resection. Its widespread use is due to its capacity to cross the blood-brain barrier and cause DNA damage in order to cytotoxically affect rapidly dividing tumour cells. Moreover, temozolomide is used as maintenance therapy after radiation therapy in the adjuvant context (also referred to as concurrent chemoradiotherapy).

Region with largest share:

When it comes to the market for treatments for Glioblastoma Multiforme (GBM), North America usually has the largest share. Numerous elements contribute to this dominance, such as the high incidence of GBM cases, the sophisticated medical technology, the long-standing healthcare infrastructure, and the significant investments made in research and development. Furthermore, North America's concentration of major healthcare facilities, academic research centres, and market players encourages innovation and makes it easier for GBM patients to adopt cutting-edge treatment modalities. The region leads the industry in GBM treatment due in part to strong regulatory frameworks, favourable reimbursement policies, and a supportive regulatory environment.

Region with highest CAGR:

In the market for treatments for glioblastoma multiforme (GBM), the Asia-Pacific region is projected to grow at the highest CAGR. Factors like the rising prevalence of GBM, rising healthcare costs, increased access to cutting-edge medical facilities, and rising R&D spending in nations like China, India, Japan, and South Korea are driving this growth. Additionally, the growth of the market in the region is also influenced by initiatives to strengthen treatment facilities, advance early detection, and increase public and professional knowledge of GBM.

Key players in the market

Some of the key players in Glioblastoma Multiforme Treatment market include F. Hoffmann-La Roche Ltd., Agenus Inc., Merck & Co., Inc., Tocagen Inc., AbbVie Inc., Merrimack Pharmaceuticals Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Orbus Therapeutics Inc., Novartis AG, Activartis GmbH, DelMar Pharmaceuticals, Inc., BTG International Ltd, GT Medical Technologies, Inc. and Celldex Therapeutics Inc.

Key Developments:

In January 2024, Merck, a leading science and technology company, has announced a licensing agreement with US-based firm Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line treatment of RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).

In December 2023, Agenus Inc., a leader in developing novel immunological agents to treat various cancers, today announced it has triggered the second development milestone payment under its global licensing agreement with Bristol Myers Squibb for BMS-986442, an Fc-enhanced bispecific TIGIT antibody. Agenus will receive a $25 million cash payment from Bristol Myers Squibb with the dosing of the first patient in the phase 2 dose expansion portion of the ongoing CA115-001 clinical trial of BMS-986442.
 
In December 2023, Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

Types Covered:
• Surgery
• Radiation Therapy
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Tumor Treating Field (TTF) Therapy
• Other Types
 
Drug Classes Covered:
• Temozolomide
• Lomustine
• Bevacizumab
• Carmustine Wafers
• Other Drug Classes

Applications Covered:
• Newly Diagnosed Glioblastoma 
• Recurrent Glioblastoma 
• Palliative Care
• Clinical Trials 
• Pediatric Glioblastoma 
• Other Applications

End Users Covered:
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan        
o China        
o India        
o Australia  
o New Zealand
o South Korea
o Rest of Asia Pacific    
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa 
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Free Customization Offerings: 
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary         
          
2 Preface         
 2.1 Abstract        
 2.2 Stake Holders        
 2.3 Research Scope        
 2.4 Research Methodology        
  2.4.1 Data Mining       
  2.4.2 Data Analysis       
  2.4.3 Data Validation       
  2.4.4 Research Approach       
 2.5 Research Sources        
  2.5.1 Primary Research Sources       
  2.5.2 Secondary Research Sources       
  2.5.3 Assumptions       
          
3 Market Trend Analysis         
 3.1 Introduction        
 3.2 Drivers        
 3.3 Restraints        
 3.4 Opportunities        
 3.5 Threats        
 3.6 Application Analysis        
 3.7 End User Analysis        
 3.8 Emerging Markets        
 3.9 Impact of Covid-19        
          
4 Porters Five Force Analysis         
 4.1 Bargaining power of suppliers        
 4.2 Bargaining power of buyers        
 4.3 Threat of substitutes        
 4.4 Threat of new entrants        
 4.5 Competitive rivalry        
          
5 Global Glioblastoma Multiforme Treatment Market, By Type         
 5.1 Introduction        
 5.2 Surgery        
 5.3 Radiation Therapy        
 5.4 Chemotherapy        
 5.5 Immunotherapy        
 5.6 Targeted Therapy        
 5.7 Tumor Treating Field (TTF) Therapy        
 5.8 Other Types        
          
6 Global Glioblastoma Multiforme Treatment Market, By Drug Class         
 6.1 Introduction        
 6.2 Temozolomide        
 6.3 Lomustine        
 6.4 Bevacizumab        
 6.5 Carmustine Wafers        
 6.6 Other Drug Classes        
          
7 Global Glioblastoma Multiforme Treatment Market, By Application         
 7.1 Introduction        
 7.2 Newly Diagnosed Glioblastoma   
 7.3 Recurrent Glioblastoma        
 7.4 Palliative Care        
 7.5 Clinical Trials         
 7.6 Pediatric Glioblastoma      
 7.7 Other Applications        
          
8 Global Glioblastoma Multiforme Treatment Market, By End User         
 8.1 Introduction        
 8.2 Hospitals        
 8.3 Ambulatory Surgical Centers        
 8.4 Clinics        
 8.5 Other End Users        
          
9 Global Glioblastoma Multiforme Treatment Market, By Geography         
 9.1 Introduction        
 9.2 North America        
  9.2.1 US       
  9.2.2 Canada       
  9.2.3 Mexico       
 9.3 Europe        
  9.3.1 Germany       
  9.3.2 UK       
  9.3.3 Italy       
  9.3.4 France       
  9.3.5 Spain       
  9.3.6 Rest of Europe       
 9.4 Asia Pacific        
  9.4.1 Japan       
  9.4.2 China       
  9.4.3 India       
  9.4.4 Australia       
  9.4.5 New Zealand       
  9.4.6 South Korea       
  9.4.7 Rest of Asia Pacific       
 9.5 South America        
  9.5.1 Argentina       
  9.5.2 Brazil       
  9.5.3 Chile       
  9.5.4 Rest of South America       
 9.6 Middle East & Africa        
  9.6.1 Saudi Arabia       
  9.6.2 UAE       
  9.6.3 Qatar       
  9.6.4 South Africa       
  9.6.5 Rest of Middle East & Africa       
          
10 Key Developments         
 10.1 Agreements, Partnerships, Collaborations and Joint Ventures        
 10.2 Acquisitions & Mergers        
 10.3 New Product Launch        
 10.4 Expansions        
 10.5 Other Key Strategies        
          
11 Company Profiling         
 11.1 F. Hoffmann-La Roche Ltd.        
 11.2 Agenus Inc.        
 11.3 Merck & Co., Inc.        
 11.4 Tocagen Inc.         
 11.5 AbbVie Inc.        
 11.6 Merrimack Pharmaceuticals Inc.        
 11.7 Eli Lilly and Company         
 11.8 Bristol-Myers Squibb Company        
 11.9 Pfizer Inc.         
 11.10 Orbus Therapeutics Inc.         
 11.11 Novartis AG         
 11.12 Activartis GmbH        
 11.13 DelMar Pharmaceuticals, Inc.         
 11.14 BTG International Ltd         
 11.15 GT Medical Technologies, Inc.         
 11.16 Celldex Therapeutics Inc.        
          
List of Tables          
1 Global Glioblastoma Multiforme Treatment Market Outlook, By Region (2021-2030) ($MN)         
2 Global Glioblastoma Multiforme Treatment Market Outlook, By Type (2021-2030) ($MN)         
3 Global Glioblastoma Multiforme Treatment Market Outlook, By Surgery (2021-2030) ($MN)         
4 Global Glioblastoma Multiforme Treatment Market Outlook, By Radiation Therapy (2021-2030) ($MN)         
5 Global Glioblastoma Multiforme Treatment Market Outlook, By Chemotherapy (2021-2030) ($MN)         
6 Global Glioblastoma Multiforme Treatment Market Outlook, By Immunotherapy (2021-2030) ($MN)         
7 Global Glioblastoma Multiforme Treatment Market Outlook, By Targeted Therapy (2021-2030) ($MN)         
8 Global Glioblastoma Multiforme Treatment Market Outlook, By Tumor Treating Field (TTF) Therapy (2021-2030) ($MN)         
9 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Types (2021-2030) ($MN)         
10 Global Glioblastoma Multiforme Treatment Market Outlook, By Drug Class (2021-2030) ($MN)         
11 Global Glioblastoma Multiforme Treatment Market Outlook, By Temozolomide (2021-2030) ($MN)         
12 Global Glioblastoma Multiforme Treatment Market Outlook, By Lomustine (2021-2030) ($MN)         
13 Global Glioblastoma Multiforme Treatment Market Outlook, By Bevacizumab (2021-2030) ($MN)         
14 Global Glioblastoma Multiforme Treatment Market Outlook, By Carmustine Wafers (2021-2030) ($MN)         
15 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)         
16 Global Glioblastoma Multiforme Treatment Market Outlook, By Application (2021-2030) ($MN)         
17 Global Glioblastoma Multiforme Treatment Market Outlook, By Newly Diagnosed Glioblastoma (2021-2030) ($MN)         
18 Global Glioblastoma Multiforme Treatment Market Outlook, By Recurrent Glioblastoma (2021-2030) ($MN)         
19 Global Glioblastoma Multiforme Treatment Market Outlook, By Palliative Care (2021-2030) ($MN)         
20 Global Glioblastoma Multiforme Treatment Market Outlook, By Clinical Trials (2021-2030) ($MN)         
21 Global Glioblastoma Multiforme Treatment Market Outlook, By Pediatric Glioblastoma (2021-2030) ($MN)         
22 Global Glioblastoma Multiforme Treatment Market Outlook, By Other Applications (2021-2030) ($MN)         
23 Global Glioblastoma Multiforme Treatment Market Outlook, By End User (2021-2030) ($MN)         
24 Global Glioblastoma Multiforme Treatment Market Outlook, By Hospitals (2021-2030) ($MN)         
25 Global Glioblastoma Multiforme Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)         
26 Global Glioblastoma Multiforme Treatment Market Outlook, By Clinics (2021-2030) ($MN)         
27 Global Glioblastoma Multiforme Treatment Market Outlook, By Other End Users (2021-2030) ($MN)         
          
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.          

List of Figures

RESEARCH METHODOLOGY


Research Methodology

We at Stratistics opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.

Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.

Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.

Data Mining

The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.

Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.

Data Analysis

From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:

  • Product Lifecycle Analysis
  • Competitor analysis
  • Risk analysis
  • Porters Analysis
  • PESTEL Analysis
  • SWOT Analysis

The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.


Data Validation

The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.

We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants

Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.


For more details about research methodology, kindly write to us at info@strategymrc.com

Frequently Asked Questions

In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.

Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.

All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929

We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

We have 3 different licensing options available in electronic format.

  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.

All our reports are typically be emailed to you as an attachment.

To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.

We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

Request Customization

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

WHY CHOOSE US ?

Assured Quality

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Free Customization

Adding more values to your product of interest.

Safe and Secure Access

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials